论文信息 - Expression and Nuclear Localization of ErbB3 in Prostate Cancer

Expression and Nuclear Localization of ErbB3 in Prostate Cancer

Purpose: The ErbB1 and ErbB2 receptors have been implicated in prostate cancer progression, but less is known about the role and biology of other ErbB receptor family members in prostate cancer. The aim of this study was to analyze the expression and localization of ErbB3 in prostate tissues and prostate cancer cell lines. Experimental Design: Immunohistochemistry of ErbB3 was done on prostate cancer tissue sections from 143 patients and on a tissue microarray containing 390 cores of radical prostatectomy-derived specimens representing normal, prostatic intraepithelial neoplasia, and malignant tissues from 81 patients. ErbB3 subcellular localization was studied by Western blot analysis in LNCaP, 22Rv1, PC-3, and DU145 prostate cancer cell lines. Results: Immunohistochemistry analysis of prostate cancer tissues revealed that >90% of prostate cancer tissues displayed cytoplasmic ErbB3 staining. Minimal ErbB3 nuclear staining was observed in normal prostate tissues and benign prostatic hyperplasia tissues; in contrast, ErbB3 was frequently localized in the nucleus of cancerous tissues. This nuclear localization was more frequent (P < 0.001) in hormone-refractory tissues (17 of 17, 100%) compared with hormone-sensitive samples (37 of 92, 40.2%). Additionally, in the tissue microarray, increased nuclear ErbB3 was associated with increasing Gleason grade. Interestingly, Western blot analysis of cytoplasmic and nuclear subcellular fractions showed that ErbB3 nuclear localization was more prevalent in hormone-sensitive prostate cancer cell lines (LNCaP and 22Rv1) compared with hormone-insensitive cell lines (PC-3 and DU145). Conclusions: ErbB3 nuclear localization discriminates normal from malignant prostate tissues and between tumors from hormone-sensitive versus hormone-refractory prostate cancer. ErbB3 nuclear staining seems to be associated with risk of disease progression. The high frequency of ErbB3 nuclear localization in hormone-refractory tissues indicates that ErbB3 warrants further study to understand its association with prostate cancer disease progression.

[1] M. Kraus,et al. Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[2] I. Ellis,et al. Production and characterization of a polyclonal antibody to the c‐erbB‐3 protein: Examination of c‐erbB‐3 protein expression in adenocarcinomas , 1992, The Journal of pathology.

[3] N. Lemoine,et al. Expression of the c-erbB-3 protein in normal human adult and fetal tissues. , 1992, Oncogene.

[4] W. Grizzle,et al. Expression of p160erbB-3 and p185erbB-2 in prostatic intraepithelial neoplasia and prostatic adenocarcinoma. , 1994, Journal of the National Cancer Institute.

[5] Y. Yoshihama,et al. Prognostic significance of ERRB3 overexpression in oral squamous cell carcinoma , 1995 .

[6] Prognostic significance of ERBB3 overexpression in oral squamous cell carcinoma. , 1995, Cancer letters.

[7] A. Mes-Masson,et al. Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. , 1996, Cancer letters.

[8] Gullick Wj. The c-erbB3/HER3 receptor in human cancer. , 1996 .

[9] W. Gullick. The c-erbB3/HER3 receptor in human cancer. , 1996, Cancer surveys.

[10] J. Rodrigo,et al. Amplification of ERBB oncogenes in squamous cell carcinomas of the head and neck , 1996 .

[11] J. Rhim,et al. ErbB kinases and NDF signaling in human prostate cancer cells , 1997, Oncogene.

[12] Mark A. Stephenson,et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. , 1997, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[13] M. Melhem,et al. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. , 1997, The cancer journal from Scientific American.

[14] W. Gullick,et al. A potential autocrine loop between heregulin-alpha and erbB-3 receptor in human prostatic adenocarcinoma. , 1997, British journal of urology.

[15] W. Russell,et al. Hepatic expression of ErbB3 is repressed by insulin in a pathway sensitive to PI-3 kinase inhibitors. , 1997, Endocrinology.

[16] Yosef Yarden,et al. Neuregulins and Their Receptors: A Versatile Signaling Module in Organogenesis and Oncogenesis , 1997, Neuron.

[17] Kuala Lumpur Malaysia,et al. Expression of c-erbB3 protein in primary breast carcinomas. , 1998, British Journal of Cancer.

[18] H. Kung,et al. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells , 1998, Nature.

[19] W. Gullick,et al. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 Growth Factor Receptors and Their Ligands, Neuregulin-1 α, Neuregulin-1 β, and Betacellulin, in Normal Endometrium and Endometrial Cancer , 1999 .

[20] W. Gullick,et al. Expression of the c-erbB-3/HER-3 and c-erbB-4/HER-4 growth factor receptors and their ligands, neuregulin-1 alpha, neuregulin-1 beta, and betacellulin, in normal endometrium and endometrial cancer. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21] D. Barnes,et al. Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers. , 2000, Cancer research.

[22] J. Manola,et al. Her-2-neu expression and progression toward androgen independence in human prostate cancer. , 2000, Journal of the National Cancer Institute.

[23] H. Kishimoto,et al. Increased expression of c‐erbB‐3 protein and proliferating cell nuclear antigen during development of verrucous carcinoma of the oral mucosa , 2000, Cancer.

[24] Monilola A. Olayioye,et al. The ErbB signaling network: receptor heterodimerization in development and cancer , 2000, The EMBO journal.

[25] Y. Yarden,et al. Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[26] J. Hsuan,et al. EGF receptors as transcription factors: ridiculous or sublime? , 2001, Nature Cell Biology.

[27] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.

[28] Y. Yarden. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. , 2001, European journal of cancer.

[29] K. Makino,et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor , 2001, Nature Cell Biology.

[30] Localizing the EGF receptor , 2002, Nature Cell Biology.

[31] R. Autorino,et al. Expression of epidermal growth factor receptor (EGFR) correlates with disease relapse and progression to androgen-indepedence in human prostate cancer , 2002 .

[32] S. Coughlin,et al. A review of genetic polymorphisms and prostate cancer risk. , 2002, Annals of epidemiology.

[33] Y. Shang,et al. Formation of the androgen receptor transcription complex. , 2002, Molecular cell.

[34] Qianben Wang,et al. Repression of androgen receptor mediated transcription by the ErbB-3 binding protein, Ebp1 , 2002, Oncogene.

[35] Stefania Staibano,et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36] F. Maurer,et al. The ErbB 2 ErbB 3 heterodimer functions as an oncogenic unit : ErbB 2 requires ErbB 3 to drive breast tumor cell proliferation , 2003, Nature Reviews. Cancer.

[37] J. D. de Vicente,et al. Expression of ErbB-3 and ErbB-4 protooncogene proteins in oral squamous cell carcinoma: a pilot study. , 2003, Medicina oral : organo oficial de la Sociedad Espanola de Medicina Oral y de la Academia Iberoamericana de Patologia y Medicina Bucal.

[38] L. Lessard,et al. NF-kappa B nuclear localization and its prognostic significance in prostate cancer. , 2003, BJU international.

[39] N. Hynes,et al. The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.

[40] J. R. Reeves,et al. Outcome and human epidermal growth factor receptor (HER) 1–4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling , 2004, Breast Cancer Research.

[41] M. Iacocca,et al. Human epidermal receptor-2 expression in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42] L. Morrison,et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. , 2003, Cancer research.

[43] A. Iwamatsu,et al. Activation of ErbB3–PI3-kinase pathway is correlated with malignant phenotypes of adenocarcinomas , 2003, Oncogene.

[44] F. Maurer,et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[45] G. Carpenter,et al. ErbB-4: mechanism of action and biology. , 2003, Experimental cell research.

[46] L. Lessard,et al. NF‐κB nuclear localization and its prognostic significance in prostate cancer , 2003 .

[47] S. Fosså,et al. Expression of the epidermal growth factor receptor family in prostate carcinoma before and during androgen-independence , 2004, British Journal of Cancer.

[48] T. Giordano,et al. Cell Surface Expression of Epidermal Growth Factor Receptor and Her-2 with Nuclear Expression of Her-4 in Primary Osteosarcoma , 2004, Cancer Research.

[49] M. Hung,et al. Binding at and transactivation of the COX-2 promoter by nuclear tyrosine kinase receptor ErbB-2. , 2004, Cancer cell.

[50] G. Devries,et al. Localization of neuregulin isoforms and erbB receptors in myelinating glial cells , 2004, Glia.

[51] J. Kern,et al. Autocrine activation of ErbB2/ErbB3 receptor complex by NRG-1 in non-small cell lung cancer cell lines. , 2004, Lung cancer.

[52] W. Gullick,et al. The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancer , 2004, Breast Cancer Research and Treatment.

[53] Ingo K Mellinghoff,et al. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. , 2004, Cancer cell.